Skip to main content
. 2022 Jun 24;4(1):vdac089. doi: 10.1093/noajnl/vdac089

Figure 1.

Figure 1.

Feasibility and safety. (A) Study schema. TMZ, temozolomide. (B) Adverse events at least possibly attributed to the treatment (vaccine plus temozolomide). (C) Adverse events regardless of attribution.